FDA simplifies liver monitoring schedule from monthly to every three months for the duration of treatment and removes embryo-fetal toxicity REMS monitoring SAN DIEGO, August 27, 2025--(BUSINESS WIRE)- ...
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) requirements for all currently approved BCMA- ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback